Development and Validation of a Diagnostic DNA Microarray To Detect Quinolone-Resistant Escherichia coli among Clinical Isolates

ABSTRACT The incidence of resistance against fluoroquinolones among pathogenic bacteria has been increasing in accordance with the worldwide use of this drug. Escherichia coli is one of the most relevant species for quinolone resistance. In this study, a diagnostic microarray for single-base-mutation detection was developed, which can readily identify the most prevalent E. coli genotypes leading to quinolone resistance. Based on genomic sequence analysis using public databases and our own DNA sequencing results, two amino acid positions (83 and 87) on the A subunit of the DNA gyrase, encoded by the gyrA gene, have been identified as mutation hot spots and were selected for DNA microarray detection. Oligonucleotide probes directed against these two positions were designed so that they could cover the most important resistance-causing and silent mutations. The performance of the array was validated with 30 clinical isolates of E. coli from four different hospitals in Germany. The microarray results were confirmed by standard DNA sequencing and were in full agreement with phenotypic antimicrobial susceptibility testing.

[1]  J. Smith.  The mode of action of 4-quinolones and possible mechanisms of resistance. , 1986, The Journal of antimicrobial chemotherapy.

[2]  A. Mirzabekov,et al.  Detection of Rifampicin-Resistant Mycobacterium tuberculosis Strains by Hybridization and Polymerase Chain Reaction on a Specialized TB-Microchip , 2004, Bulletin of Experimental Biology and Medicine.

[3]  I. Phillips,et al.  Detection of ciprofloxacin resistance in gram-negative bacteria due to alterations in gyrA. , 1992, The Journal of antimicrobial chemotherapy.

[4]  J. Yoo,et al.  Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  S. Karlin,et al.  Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Lu,et al.  Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. , 2001, Microbial drug resistance.

[7]  G. Jacoby.  Mechanisms of resistance to quinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Hooper.  Mechanisms of fluoroquinolone resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[9]  S. Nakamura,et al.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli , 1990, Antimicrobial Agents and Chemotherapy.

[10]  K. Gunderson,et al.  Mutation detection by ligation to complete n-mer DNA arrays. , 1998, Genome research.

[11]  A. Mirzabekov,et al.  Identification of Rifampin-Resistant Mycobacterium tuberculosis Strains by Hybridization, PCR, and Ligase Detection Reaction on Oligonucleotide Microchips , 2001, Journal of Clinical Microbiology.

[12]  K U Mir,et al.  Arrays of complementary oligonucleotides for analysing the hybridisation behaviour of nucleic acids. , 1994, Nucleic acids research.

[13]  P. Heisig,et al.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli , 1996, Antimicrobial agents and chemotherapy.

[14]  W. Fu,et al.  Use of a rapid mismatch PCR method to detect gyrA and parC mutations in ciprofloxacin-resistant clinical isolates of Escherichia coli. , 2002, The Journal of antimicrobial chemotherapy.

[15]  A. Wyke,et al.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones , 1989, Antimicrobial Agents and Chemotherapy.

[16]  W. Kern,et al.  gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. , 1996, The Journal of antimicrobial chemotherapy.

[17]  D. Hooper,et al.  Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations , 1995, Antimicrobial agents and chemotherapy.

[18]  J. Odeberg,et al.  Genotyping by apyrase-mediated allele-specific extension. , 2001, Nucleic acids research.

[19]  L. Gutmann,et al.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid , 1991, Antimicrobial Agents and Chemotherapy.

[20]  I. Tinoco,et al.  Base pairing involving deoxyinosine: implications for probe design. , 1985, Nucleic acids research.

[21]  M. Drebot,et al.  Design of oligonucleotide arrays to detect point mutations: molecular typing of antibiotic resistant strains of Neisseria gonorrhoeae and hantavirus infected deer mice. , 2003, Molecular and cellular probes.

[22]  N. Moreau,et al.  Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. , 1993, Journal of Antimicrobial Chemotherapy.

[23]  G. Crumplin.  Mechanisms of resistance to the 4-quinolone antibacterial agents. , 1990, The Journal of antimicrobial chemotherapy.

[24]  S. Mitsuhashi,et al.  Norfloxacin resistance in a clinical isolate of Escherichia coli , 1987, Antimicrobial Agents and Chemotherapy.

[25]  D. Hooper,et al.  Mechanisms of action of and resistance to ciprofloxacin. , 1987, The American journal of medicine.

[26]  M. E. Cullen,et al.  Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance. , 1989, The American journal of medicine.

[27]  A. Khodursky,et al.  Topoisomerase IV is a target of quinolones in Escherichia coli. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  John E. Linz,et al.  Identification of Ciprofloxacin-ResistantCampylobacter jejuni by Use of a Fluorogenic PCR Assay , 2000, Journal of Clinical Microbiology.

[29]  S. Levy,et al.  Ineffectiveness of Topoisomerase Mutations in Mediating Clinically Significant Fluoroquinolone Resistance inEscherichia coli in the Absence of the AcrAB Efflux Pump , 2000, Antimicrobial Agents and Chemotherapy.

[30]  L Peltonen,et al.  Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays. , 1997, Genome research.

[31]  A. Troesch,et al.  Mycobacterium Species Identification and Rifampin Resistance Testing with High-Density DNA Probe Arrays , 1999, Journal of Clinical Microbiology.

[32]  L. Piddock,et al.  Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals , 1996, Antimicrobial agents and chemotherapy.

[33]  E. Southern,et al.  Molecular interactions on microarrays , 1999, Nature Genetics.

[34]  C. Nusbaum,et al.  Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. , 1998, Science.

[35]  P. Heisig,et al.  Impact of gyrA and parCMutations on Quinolone Resistance, Doubling Time, and Supercoiling Degree of Escherichia coli , 1999, Antimicrobial Agents and Chemotherapy.

[36]  L. Ng,et al.  Characterization of Ciprofloxacin Resistance in Neisseria gonorrhoeae Isolates in Canada , 2002, Sexually transmitted diseases.

[37]  P. Heisig,et al.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro , 1994, Antimicrobial Agents and Chemotherapy.

[38]  R. Hopewell,et al.  New Concepts on the Mechanism of Action and Resistance , 1989 .